News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
UCB plans to submit regulatory applications in Q3 2022
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Subscribe To Our Newsletter & Stay Updated
